Literature DB >> 8762063

Potent antagonism by BIM-23056 at the human recombinant somatostatin sst5 receptor.

G F Wilkinson1, R J Thurlow, L A Sellers, J E Coote, W Feniuk, P P Humphrey.   

Abstract

We have investigated the effects of somatostatin (SRIF) and the linear octapeptide BIM-23056 on changes in intracellular calcium ion concentration ([Ca2+]i) and on the formation of inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) in CHO-K1 cells transfected with the human recombinant SRIF sst5 receptor. SRIF elicited concentration-dependent increases in [Ca2+]i, with a pEC50 of 7.02 +/- 0.06, while BIM-23056 (1 x 10(-7) M) behaved not as an agonist but as a potent, surmountable antagonist of these increases in [Ca2+]i. The SRIF concentration-effect curve for increases in [Ca2+]i was shifted rightward producing an estimated pKB for the antagonist of 8.0. BIM-23056 (1 x 10(-7) M) also significantly attenuated Ins(1,4,5)P3 increases due to SRIF, but had no effect on either basal or uridine 5'-triphosphate (UTP) (1 x 10(-4) M) stimulated increases in the levels of [Ca2+]i or Ins(1,4,5)P3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762063      PMCID: PMC1909702          DOI: 10.1111/j.1476-5381.1996.tb15423.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

1.  Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein.

Authors:  S Rees; J Coote; J Stables; S Goodson; S Harris; M G Lee
Journal:  Biotechniques       Date:  1996-01       Impact factor: 1.993

Review 2.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology.

Authors:  D H Jenkinson; E A Barnard; D Hoyer; P P Humphrey; P Leff; N P Shankley
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

3.  Classification and nomenclature of somatostatin receptors.

Authors:  D Hoyer; G I Bell; M Berelowitz; J Epelbaum; W Feniuk; P P Humphrey; A M O'Carroll; Y C Patel; A Schonbrunn; J E Taylor
Journal:  Trends Pharmacol Sci       Date:  1995-03       Impact factor: 14.819

4.  Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).

Authors:  Y C Patel; C B Srikant
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

5.  Phospholipase C activation and Ca2+ mobilization by cloned human somatostatin receptor subtypes 1-5, in transfected COS-7 cells.

Authors:  M Akbar; F Okajima; H Tomura; M A Majid; Y Yamada; S Seino; Y Kondo
Journal:  FEBS Lett       Date:  1994-07-11       Impact factor: 4.124

6.  Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype.

Authors:  Y Yamada; S Kagimoto; A Kubota; K Yasuda; K Masuda; Y Someya; Y Ihara; Q Li; H Imura; S Seino
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

  6 in total
  8 in total

1.  Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation.

Authors:  R Colucci; C Blandizzi; N Ghisu; T Florio; M Del Tacca
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

2.  Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides.

Authors:  F Alderton; T P Fan; P P Humphrey
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

3.  Somatostatin sst2 receptor-mediated inhibition of parietal cell function in rat isolated gastric mucosa.

Authors:  M A Wyatt; E Jarvie; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

4.  Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Galphas proteins.

Authors:  A M Carruthers; A J Warner; A D Michel; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

5.  Evidence that somatostatin sst2 receptors mediate striatal dopamine release.

Authors:  G J Hathway; P P Humphrey; K M Kendrick
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells.

Authors:  C Petrucci; D Cervia; M Buzzi; C Biondi; P Bagnoli
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

7.  A functional comparison of recombinant and native somatostatin sst2 receptor variants in epithelia.

Authors:  N D Holliday; I R Tough; H M Cox
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

8.  Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-dependent apoptosis that protect mice from acute liver failure.

Authors:  A P Komarov; E A Komarova; K Green; L R Novototskaya; P S Baker; A Eroshkin; A L Osterman; A A Chenchick; C Frangou; A V Gudkov
Journal:  Cell Death Dis       Date:  2016-03-17       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.